Costunolide attenuates LPS-induced inflammation and lung injury through inhibiting IKK/NF-κB signaling
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Inflammation is an important pathological process of many acute and chronic diseases, such as sepsis, arthritis, and cancer. Many factors can lead to an inflammatory state of the body, among which bacterial infection plays an important role. Bacterial infection often leads to sepsis, acute lung injury (ALI), or its more serious form of acute respiratory distress syndrome, which are the main fatal diseases in intensive care units. Costunolide has been reported to possess excellent anti-inflammatory activity; however, whether it can affect inflammation induced by gram-negative bacterial is still unclear. Lipopolysaccharide (LPS) stimulated mouse peritoneal macrophages (MPMs) to release proinflammatory cytokines was used as the cell model. The mouse model of sepsis and ALI was built through injecting intravenously and intratracheally of LPS. In the present study, costunolide inhibited LPS-induced inflammatory response through IKK/NF-κB signaling pathway in macrophages. In vivo, costunolide attenuated LPS-induced septic death in mice. Meanwhile, costunolide treatment alleviated LPS-induced lung injury and inflammation via inhibiting the infiltration of inflammatory cells and the expression of inflammatory cytokines. Taken together, these results demonstrated that costunolide could attenuate gram-negative bacterial induced inflammation and diseases and might be a potential candidate for the treatment of inflammatory diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:397 |
|---|---|
| Enthalten in: |
Naunyn-Schmiedeberg's archives of pharmacology - 397(2024), 3 vom: 03. Feb., Seite 1601-1610 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Xiaona [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4IK578SA7Z |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 15.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00210-023-02705-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361861125 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361861125 | ||
| 003 | DE-627 | ||
| 005 | 20240215231910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00210-023-02705-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM361861125 | ||
| 035 | |a (NLM)37688623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Xiaona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Costunolide attenuates LPS-induced inflammation and lung injury through inhibiting IKK/NF-κB signaling |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Inflammation is an important pathological process of many acute and chronic diseases, such as sepsis, arthritis, and cancer. Many factors can lead to an inflammatory state of the body, among which bacterial infection plays an important role. Bacterial infection often leads to sepsis, acute lung injury (ALI), or its more serious form of acute respiratory distress syndrome, which are the main fatal diseases in intensive care units. Costunolide has been reported to possess excellent anti-inflammatory activity; however, whether it can affect inflammation induced by gram-negative bacterial is still unclear. Lipopolysaccharide (LPS) stimulated mouse peritoneal macrophages (MPMs) to release proinflammatory cytokines was used as the cell model. The mouse model of sepsis and ALI was built through injecting intravenously and intratracheally of LPS. In the present study, costunolide inhibited LPS-induced inflammatory response through IKK/NF-κB signaling pathway in macrophages. In vivo, costunolide attenuated LPS-induced septic death in mice. Meanwhile, costunolide treatment alleviated LPS-induced lung injury and inflammation via inhibiting the infiltration of inflammatory cells and the expression of inflammatory cytokines. Taken together, these results demonstrated that costunolide could attenuate gram-negative bacterial induced inflammation and diseases and might be a potential candidate for the treatment of inflammatory diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Acute lung injury | |
| 650 | 4 | |a Costunolide | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Lipopolysaccharide | |
| 650 | 4 | |a Sepsis | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Lipopolysaccharides |2 NLM | |
| 650 | 7 | |a costunolide |2 NLM | |
| 650 | 7 | |a 4IK578SA7Z |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Sesquiterpenes |2 NLM | |
| 700 | 1 | |a Bai, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Xiangting |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Zhongxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Letong |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yelin |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Yuanrong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Naunyn-Schmiedeberg's archives of pharmacology |d 1972 |g 397(2024), 3 vom: 03. Feb., Seite 1601-1610 |w (DE-627)NLM000008354 |x 1432-1912 |7 nnns |
| 773 | 1 | 8 | |g volume:397 |g year:2024 |g number:3 |g day:03 |g month:02 |g pages:1601-1610 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00210-023-02705-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 397 |j 2024 |e 3 |b 03 |c 02 |h 1601-1610 | ||